- Positions RECCE® 327 (R327) gel as a potential broad topical therapeutic for all bacterial skin infections
Human Research Ethics Committee approval received for Phase II trial of R327 for acute bacterial skin and skin structure infections (ABSSSI), including diabetic foot and wound infections- New site initiation commenced with first patients to be dosed in Q3 2024
- This trial builds upon clinical results of R327 tested against burn wound and diabetic foot infections
“Obtaining HREC approval marks another significant milestone for Recce and the clinicians striving to discover an effective treatment for ABSSSIs,” said
The Phase II trial is an open-label, efficacy study and exploratory evaluation of the systemic bioavailability of single and/or multiple doses of R327 topical gel applied to ABSSSI. The study aims to provide critical data on the R327’s effectiveness in treating a broad range of ABSSSI indications. ABSSSI refers to a bacterial infection of the skin and its related tissues. Examples of skin conditions commonly included in that category are diabetic foot infections (DFI), necrotizing fasciitis, post-operative wound infections, and more.
This study approval allows the Company to bring together the clinical studies of DFIs, wound infections, and more under one key centralized regulatory category of ABSSSI for a broad range of unmet medical needs in the topical bacterial infection landscape. This centralized approach has been made possible by building upon the validated study data to date, including compelling patient outcomes under the TGA Special Access Scheme Category A initiatives.
The study is to be commenced at
The global ABSSSI treatment market size was valued at
ABSSSIs present a considerable challenge to the healthcare system. While new antibiotic treatments have recently been developed to combat Gram-positive organisms, there remains a crucial need for antibiotics to address both Gram-positive and Gram-negative pathogens. Furthermore, the rise of antimicrobial resistance in both Gram-positive and Gram-negative bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA), presents a growing challenge in treating these infections,2 with a particular focus on the increase in the prevalence of MRSA being detected among hospitalized patients. Those particularly at high risk of skin infections and poor outcomes from ABSSSI are patients with diabetes.3
About
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.
The
Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.
Corporate Contact
+61 (02) 9256 2571
James.graham@recce.com.au
Media & Investor Relations (AU)
CityPR
+61 (02) 9267 4511
ageddes@citypublicrelations.com.au
Media (
mfitzhugh@lifescicomms.com
Investor Relations (
gvanrenterghem@lifesciadvisors.com
1 https://www.fortunebusinessinsights.com/industry-reports/acute-bacterial-skin-and-skin-structure-infections-absssi-treatment-market-100971
2 https://www.altmeyers.org/en/dermatology/absssi-132569
3 https://www.sciencedirect.com/science/article/pii/S0168822721000851
![](https://ml.globenewswire.com/media/M2VjNWE3ZjUtYTFkYy00NTBkLWFlOWItYTQ4ODgzNWMzNWFiLTUwMDA3MTAwNA==/tiny/Recce-Pharmaceuticals.png)
2024 GlobeNewswire, Inc., source